FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
LONDON: A brawl broke out between Muslim youths and Hindus at a Holika Dahan celebration in Harrow on Tuesday night after ...
Q4 2025 Management View CEO Mark Baum highlighted, “Harrow now owns one of the largest portfolios of prescription ophthalmic products in the United States market, and we have been the most prolific ...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that ...
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting ...
Harrow Times on MSN
The iconic Harrow factory still shaping the area's identity 120 years on
Barratt London hosts interactive tour at Harrow’s former Kodak site, now Eastman Village, blending heritage with 2,250 new ...
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow Health, Inc.'s control, including risks and uncertainties described from time to time in its ...
NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an ...
Analysts expect Harrow to report an earnings per share (EPS) of $0.42. The announcement from Harrow is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance ...
At Lord’s Cricket Ground in the quiet, well-heeled streets of northwest London, different architectural eras collide together in a mishmash of mismatching styles representing the old and the new. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results